Medizinische Universitaetsklinik I at the University of Cologne
Welcome,         Profile    Billing    Logout  
 16 Trials 
27 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Engert, Andreas
HD16, NCT00736320: for Early Stage Hodgkin Lymphoma

Active, not recruiting
3
1150
Europe
ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine), 20 Gy IFRT (Involved Field Radiotherapy)
University of Cologne
Hodgkin Lymphoma
09/18
12/21
NCT03652441: Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma

Recruiting
2
21
Europe
Brentuximab Vedotin, BV
University of Cologne
Classical Hodgkin Lymphoma
08/22
08/23
AERN, NCT03480334: Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy

Recruiting
2
29
Europe
Nivolumab plus radiotherapy
University of Cologne
Classical Hodgkin Lymphoma
10/23
12/24
NIVAHL, NCT03004833 / 2016-002626-37: Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma

Active, not recruiting
2
110
Europe
Nivolumab, Adriamycin, Vinblastine, Dacarbazine
University of Cologne
Classical Hodgkin Lymphoma
12/23
12/23
Pembro-CORE, NCT04838652: Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma

Not yet recruiting
2
29
Europe
Pembrolizumab plus Chemotherapy (ICE or DHAP)
University of Cologne
Classical Hodgkin Lymphoma
12/24
12/26
INDIE, NCT04837859: Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma

Not yet recruiting
2
120
Europe
Tislelizumab
University of Cologne
Classical Hodgkin Lymphoma
12/25
12/27
Wendtner, Clemens M
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Canada, Japan, US, RoW
LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
11/23
05/27
NCT05197192 / 2020-004360-26: A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

Recruiting
3
650
Europe
Obinutuzumab, Gazyva, Gazyvaro, Venetoclax, Venclexta, Venclyxto, Acalabrutinib, Calquence
German CLL Study Group, AstraZeneca
Chronic Lymphocytic Leukemia
05/26
02/27
CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting
3
897
Europe, RoW
Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro
German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG)
Chronic Lymphoid Leukemia
03/27
03/27
Eichhorst, Barbara
GAIA, NCT02950051 / 2015-004936-36: Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

Hourglass Jan 2021 - Dec 2021 : From CLL13 trial in combination with Venclexta for 1L CLL
Completed
3
926
Europe, RoW
Fludarabine, Fludura, Cyclophosphamide, Endoxan, Rituximab, MabThera, Rituxan, Bendamustine, Ribomustin, Levact, Venetoclax, Venclexta, Venclyxto, Obinutuzumab, Gazyva, Gazyvaro, Ibrutinib, Imbruvica
German CLL Study Group, Janssen-Cilag Ltd., Hoffmann-La Roche, AbbVie, Stichting Hemato-Oncologie voor Volwassenen Nederland, Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research, Cancer Trials Ireland, Israeli CLL Study Group
Chronic Lymphocytic Leukemia
02/24
02/24
NCT05197192 / 2020-004360-26: A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

Recruiting
3
650
Europe
Obinutuzumab, Gazyva, Gazyvaro, Venetoclax, Venclexta, Venclyxto, Acalabrutinib, Calquence
German CLL Study Group, AstraZeneca
Chronic Lymphocytic Leukemia
05/26
02/27
ACE-CL-311, NCT03836261: Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

Calendar Jan 2027 - Mar 2027: Last patient dosing of P3 ACE-CL-311 trial in combination with venetoclax for previously untreated CLL
Calendar Jan 2024 - Dec 2024: Data from AMPLIFY trial in combination with Calquence and obinutuzumab for previously untreated CLL
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with venclexta and obinutuzumab for 1L CLL (based on AMPLIFY trial)
Hourglass Jul 2022 - Dec 2022 : From P3 ACE-CL-311 trial in combination with Venclexta for 1L CLL
Active, not recruiting
3
984
Europe, Canada, US, RoW
Acalabrutinib, Calquence (acalabrutinib), Venetoclax, Venclyxto, Venclexta, Chemoimmunotherapy, Obinutuzumab, Gazyva, Gazyvaro
Acerta Pharma BV, AstraZeneca
Chronic Lymphocytic Leukemia
01/27
01/27
CLL-Frail, NCT04883749: Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL

Active, not recruiting
2
53
Europe
Acalabrutinib, Calquence, ACP-196
German CLL Study Group
Chronic Lymphoid Leukemia
07/23
12/24
CLL-RT1, NCT04271956: Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation

Active, not recruiting
2
57
Europe
Tislelizumab, BGB-A317, Zanubrutinib, BGB-3111
German CLL Study Group
Richter Transformation
12/23
12/24
Hallek, Michael
CLL-Registry, NCT02863692: Registry of the German CLL Study Group

Recruiting
N/A
8000
Europe
German CLL Study Group
CLL, SLL, HCL, Richter´s Transformation, Leukemia, Prolymphocytic, B-Cell, Leukemia, Prolymphocytic, T-Cell, T-LGL Leukemia, NK-LGL Leukemia
12/26
12/26
Reiser, Marcel
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology

Completed
N/A
499
Europe
iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG
Advanced Solid Tumors or Hematologic Malignancies
06/23
06/23
DigiNet, NCT05818449: Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation

Active, not recruiting
N/A
850
Europe
DigiNet intervention
University of Cologne, Gemeinsamer Bundesausschuss (G-BA), AOK Rheinland/Hamburg, AOK Nordwest, BARMER, University Hospital, Essen, Charite University, Berlin, Germany, Berlin Institute of Health, Helios Klinikum Emil von Behring, University Hospital Carl Gustav Carus, Deutsche Krebsgesellschaft e.V., Berufsverband der Niedergelassenen Hämatologen und Onkologen in Deutschland e.V., AOK Bundesverband, FOM Hochschule für Oekonomie und Management, University Medicine Greifswald, Technische Universität Dresden
Non-small Cell Lung Cancer Stage IV
03/25
03/25
ITP-Registry, NCT05152238: ITP Registry and Accompanying Biospecimen Collection

Recruiting
N/A
1100
Europe
Jena University Hospital, University Hospital Dresden, Novartis, Swedish Orphan Biovitrum, Grifols Biologicals, LLC, Amgen, argenx
Immune Thrombocytopenia
09/26
04/27
REALTRK, NCT04557813: Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion

Active, not recruiting
N/A
88
Europe
iOMEDICO AG, Roche Pharma AG
NTRK Family Gene Mutation
10/26
10/26
Person, Contact
PATCH, NCT00303784 / 2005-001030-33: Prostate Adenocarcinoma TransCutaneous Hormones

Recruiting
3
2200
Europe
Goserelin, Zoladex, Estradiol, FemSeven
University College, London, Medical Research Council
Anemia, Cardiovascular Complications, Hot Flashes, Osteoporosis, Prostate Cancer
08/21
08/21
UKALL14, NCT01085617 / 2009-012717-22: Standard Chemotherapy With or Without Nelarabine or Rituximab in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Active, not recruiting
3
1033
NA
palifermin, rituximab, cyclophosphamide, cytarabine, daunorubicin hydrochloride, etoposide, fludarabine phosphate, imatinib mesylate, melphalan, mercaptopurine, methotrexate, nelarabine, pegaspargase, vincristine sulfate, allogeneic hematopoietic stem cell transplantation, total-body irradiation
University College, London
Leukemia, Mucositis, Oral Complications
12/24
12/25
STAMPEDE, NCT00268476: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy

Active, not recruiting
2/3
11992
Europe
Celecoxib, Celebrex, Docetaxel, Taxotere, Prednisolone, Prednisone, ADT, Androgen Deprivation Therapy, Zoledronic Acid, Zometa, Abiraterone, Zytiga, Radiotherapy to the prostate, RT, Enzalutamide, Xtandi, Metformin, Metformin Hydrochloride, Transdermal Oestradiol, Progynova TS
Medical Research Council
Prostate Cancer
03/26
12/30
NCT00589017: Tamoxifen in Treating Patients With Metastatic Bladder Cancer That Did Not Respond to Previous Chemotherapy

Recruiting
2
75
US, Europe
tamoxifen citrate, immunohistochemistry staining method, laboratory biomarker analysis
Baylor College of Medicine
Bladder Cancer
07/10
 
NCT03412643: Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

Recruiting
2
64
US
Doxorubicin, Cyclophosphamide, Weekly Paclitaxel, Trastuzumab, Pertuzumab, Celcuity CELx HSF
NSABP Foundation Inc, Celcuity, LLC, Genentech, Inc.
HER2-negative Breast Cancer
10/23
10/23
PRISM, NCT03658525: Prostate Radiotherapy Integrated With Simultaneous MRI (The Study)

Recruiting
N/A
30
Europe
MR LINAC
Royal Marsden NHS Foundation Trust
Prostate Cancer
08/20
08/23
NCT06032663: Use of PET-MR in Head and Neck Cancer Patients - Diagnostic and Therapeutic Applications

Recruiting
N/A
10
Europe
PET-MRI
Sheffield Teaching Hospitals NHS Foundation Trust
Head and Neck Cancer
10/24
10/25
NCT01840293: Breast Cancer Proteomics and Molecular Heterogeneity

Recruiting
N/A
1780
Europe
Cancer Trials Ireland
Primary Breast Cancer, Recurrent/Metastatic Breast Cancer
12/29
01/38

Download Options